Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
The child was treated with antiretrovirals for only 40 weeks starting at 9 weeks of age and has since maintained a fully suppressed virus.
Researchers reveled in promising new data on forthcoming hepatitis C therapies.
Recent dire estimates about the HIV “treatment cascade” may not be as great as previously suspected.
People with untreated HIV whose CD4s drop below 350 have more than twice the risk of developing serious non-AIDS diseases as those with levels...
Two new gene therapy studies further the hopes that scientists may develop widely replicable methods to control HIV through stem cell modifica...
Gay black men have a higher risk of HIV infection than the general gay population, irrespective of number of sexual partners, injection drug u...
Adding Incivek to pegylated interferon and ribavirin doubles the cure rate and cuts in half the treatment time for acute hepatitis C among HIV...
The hep C antiviral ABT-450, combined with ribavirin and ABT-072 or ABT-333, yielded cure rates as high as 95 percent in treatment-naive study...
The rate of drug-resistant HIV transmitted among newly diagnosed people has remained constant at about one in six cases.
Forty-two percent of people with HIV in care are regular smokers, a rate twice that of the general population.
Urban gay and bisexual men’s awareness of their HIV status has increased, but the prevalence of the virus remains stable among this...
An all-oral combination therapy of sofosbuvir, ledipasvir and ribavirin boasts a 100 percent cure rate among people with hepatitis C virus.
A long-acting, injectable version of the antiretroviral dolutegravir prevented rectal transmission of simian HIV (SHIV) in eight macaques.
Interim 24-week results from a Phase III study
comparing the investigatory dolutegravir to raltegravir among
HIV-positive individuals who...
In an interim analysis, simeprevir and sofosbuvir showed high cure rates in those who had failed a hep C therapy and had mild to moderate fibr...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.